DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Portal Hypertension - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Portal Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Portal Hypertension and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Portal Hypertension Overview
- Therapeutics Development
- Pipeline Products for Portal Hypertension - Overview
- Pipeline Products for Portal Hypertension - Comparative Analysis
- Portal Hypertension - Therapeutics under Development by Companies
- Portal Hypertension - Therapeutics under Investigation by Universities/Institutes
- Portal Hypertension Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Portal Hypertension - Products under Development by Companies
- Portal Hypertension - Products under Investigation by Universities/Institutes
- Portal Hypertension - Companies Involved in Therapeutics Development
- Conatus Pharmaceuticals Inc.
- Galectin Therapeutics, Inc.
- Gilead Sciences, Inc.
- Intercept Pharmaceuticals, Inc.
- LinXis B.V.
- Mezzion Pharma Co. Ltd.
- Ono Pharmaceutical Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/q9fp3x/portal
